Follistatin-344 vs Humanin
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Follistatin-344 and Humanin (also searched as Humanin vs Follistatin-344) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Follistatin-344 centers on muscle, while Humanin leans toward healing. On indexed research, Humanin is ahead (Follistatin-344: 5 studies, Human evidence; Humanin: 7, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Follistatin-344 is strongest for muscle; Humanin for healing.
- •Evidence: Follistatin-344 Human evidence (5 studies) vs Humanin Preclinical (7).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Myostatin inhibition | Muscle growth
Mitochondria-Derived Peptide | HN
Follistatin-344 vs Humanin: side-by-side
| Metric | Follistatin-344 | Humanin |
|---|---|---|
| Class | Muscle | Longevity |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Preclinical |
| Studies indexed | 5 | 7 |
| Research level | Limited Research | Moderate Research |
| Strongest effect | Muscle & body comp | Healing & recovery |
| Healing & recovery | 1.0 | 4.0▲ |
| Muscle & body comp | 5.0▲ | 1.0 |
| Metabolic & appetite | 2.0 | 4.0▲ |
| Neuro & mood | 1.0 | 3.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 1.0 | 3.0▲ |
| Skin & aesthetics | 2.0▲ | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Follistatin-344 | Humanin |
|---|---|---|
| Mechanism | Myostatin inhibitor | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Follistatin-344?
### Follistatin-344 Summary Follistatin-344 is a glycoprotein that plays a crucial role in the regulation of muscle growth and development by inhibiting myostatin, a negative regulator of muscle mass. Its potential therapeutic applications are being explored in various fields, including muscle wasting disorders and regenerative medicine.
Full Follistatin-344 profile, mechanism & studies →What is Humanin?
Mitochondria-associated peptide explored for longevity, metabolic, and organ-protective effects.
Full Humanin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Humanin | 4.0/5 effect signal |
| Muscle | Follistatin-344 | 5.0/5 effect signal |
| Metabolic | Humanin | 4.0/5 effect signal |
| Neuro | Humanin | 3.0/5 effect signal |
| Inflammation | Humanin | 3.0/5 effect signal |
| Skin | Follistatin-344 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Follistatin-344 and Humanin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Follistatin-344 vs Humanin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Follistatin-344 has 5 approved studies indexed (Human evidence), and Humanin has 7 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Follistatin-344 or Humanin better?
It depends on your goal. Follistatin-344 is strongest for muscle; Humanin for healing. Humanin has more indexed studies (7). See the goal-by-goal breakdown above.
Is Follistatin-344 or Humanin better for weight loss?
Humanin shows the stronger metabolic & appetite profile (4.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Follistatin-344 or Humanin better for muscle?
Follistatin-344 leads on the muscle & body-composition axis (5.0/5).
Which has more research, Follistatin-344 or Humanin?
Follistatin-344 has 5 approved studies indexed (Human evidence); Humanin has 7 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack Follistatin-344 and Humanin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Follistatin-344 vs Humanin?
Follistatin-344: no community-reported effects logged yet. Humanin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Follistatin-344 or Humanin FDA-approved?
Follistatin-344 is a research-use compound and is not FDA-approved. Humanin is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Humanin better than Follistatin-344?
For healing, Humanin has the edge; for muscle, Follistatin-344 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Follistatin-344 and Humanin are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.